November 2025 in “Drug Testing and Analysis” This study investigated the metabolic pathways of epristeride, a new Type II 5α‐reductase inhibitor, using in vitro models and found that its metabolites show significant interactions with key proteins, suggesting implications for its role in doping control.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” This review discusses the efficacy and safety of exemestane as a treatment for estrogen-receptor-positive breast cancer and reports no new clinical results.
November 2012 in “Journal of the International AIDS Society” This observational study suggests that antiretroviral drugs that interact with CYP 3A4 enzymes may alter finasteride's effectiveness for hair loss in men treated for HIV.
1 citations
,
October 2023 in “Journal of the Endocrine Society” In this case report, researchers highlight a 57-year-old HIV patient on ritonavir who developed Cushing’s syndrome from over-the-counter intranasal fluticasone, underscoring the risks of drug interactions and the importance of counseling patients about potential steroid ingredients in OTC products.